Close
4

Quotient Sciences Quotient Sciences

X

Company profile for Clementia Pharmaceuticals

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
We are developing palovarotene, an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of individuals who are affected by fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas (MO) and other diseases. For FOP, we are preparing for a New Drug Application (NDA) for episodic, flare-up based palovarotene treatment, which we intend to submit to the U.S. Food and Drug Administrat...
We are developing palovarotene, an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of individuals who are affected by fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas (MO) and other diseases. For FOP, we are preparing for a New Drug Application (NDA) for episodic, flare-up based palovarotene treatment, which we intend to submit to the U.S. Food and Drug Administration (FDA) in the second half of 2019, and subject to approval, a U.S. commercial launch in the first half of 2020.We also completed enrollment in our Phase 3 MOVE Trial in FOP in August 2018.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
Clementia Pharmaceuticals
Canada Flag
Country
Country
Canada
Address
Address
1000 de la Gauchetière O, Suite 1200 Montreal, QC H3B 4W5
Telephone
Telephone
+1 (514) 940-3600

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY